Rationale and evidence on the use of tocilizumab in COVID-19: A systematic review. Authors' reply.
作者信息
Cortegiani A, Ippolito M, Einav S
机构信息
Department of Surgical, Oncological and Oral Science (Di.Chir.On.S.), University of Palermo, Italy; Department of Anesthesia, Intensive Care and Emergency, Policlinico Paolo Giaccone, University of Palermo, Palermo, Italy.
Department of Surgical, Oncological and Oral Science (Di.Chir.On.S.), University of Palermo, Italy.
出版信息
Pulmonology. 2021 Jan-Feb;27(1):87-88. doi: 10.1016/j.pulmoe.2020.10.003. Epub 2020 Oct 21.
Abstract
摘要
相似文献
1
Rationale and evidence on the use of tocilizumab in COVID-19: A systematic review. Authors' reply.托珠单抗用于新型冠状病毒肺炎的理论依据与证据：一项系统评价。作者回复
Pulmonology. 2021 Jan-Feb;27(1):87-88. doi: 10.1016/j.pulmoe.2020.10.003. Epub 2020 Oct 21.
2
Promising effects of tocilizumab in COVID-19: A non-controlled, prospective clinical trial.托珠单抗治疗 COVID-19 的疗效：一项非对照、前瞻性临床试验。
Int Immunopharmacol. 2020 Nov;88:106869. doi: 10.1016/j.intimp.2020.106869. Epub 2020 Aug 4.
3
Tocilizumab in Covid-19. Reply.托珠单抗治疗新型冠状病毒肺炎。回复。
N Engl J Med. 2021 Jan 7;384(1):87. doi: 10.1056/NEJMc2032911. Epub 2020 Dec 22.
4
Early tocilizumab treatment could improve survival among COVID-19 patients.早期使用托珠单抗治疗可提高新冠病毒疾病患者的生存率。
Clin Exp Rheumatol. 2020 May-Jun;38(3):578. Epub 2020 May 27.
5
Tocilizumab for Hemophagocytic Syndrome in a Kidney Transplant Recipient With COVID-19.托珠单抗用于一名合并 COVID-19 的肾移植受者的噬血细胞综合征
Ann Intern Med. 2020 Sep 15;173(6):501-503. doi: 10.7326/L20-0419. Epub 2020 May 18.
6
Interleukin-6 receptor antagonist therapy to treat SARS-CoV-2 driven inflammatory syndrome in a kidney transplant recipient.白细胞介素-6受体拮抗剂疗法治疗肾移植受者中由SARS-CoV-2驱动的炎症综合征。
Transpl Infect Dis. 2020 Aug;22(4):e13326. doi: 10.1111/tid.13326. Epub 2020 Jun 5.
7
Reply to Yang et al.: Tocilizumab treatment in COVID-19 patients needs the assessment of the disease severity and timely intervention.回复杨等人：托珠单抗治疗新冠病毒病患者需要评估疾病严重程度并及时干预。
Proc Natl Acad Sci U S A. 2020 Dec 1;117(48):30027-30028. doi: 10.1073/pnas.2011616117. Epub 2020 Nov 12.
8
Tocilizumab in Covid-19.托珠单抗治疗新型冠状病毒肺炎
N Engl J Med. 2021 Jan 7;384(1):86-87. doi: 10.1056/NEJMc2032911. Epub 2020 Dec 22.
9
Interleukin 6-blockade treatment for severe COVID-19 in two patients with multiple myeloma.白细胞介素6阻断疗法治疗两名多发性骨髓瘤患者的重症新型冠状病毒肺炎
Br J Haematol. 2020 Jul;190(1):e9-e11. doi: 10.1111/bjh.16787. Epub 2020 May 18.
10
COVID-19 in a patient with systemic sclerosis treated with tocilizumab for SSc-ILD.一名接受托珠单抗治疗系统性硬化症相关间质性肺病的系统性硬化症患者感染了新冠病毒。
Ann Rheum Dis. 2020 May;79(5):668-669. doi: 10.1136/annrheumdis-2020-217442. Epub 2020 Apr 2.
引用本文的文献
1
Synergistic Pulmonoprotective Effect of Natural Prolyl Oligopeptidase Inhibitors in In Vitro and In Vivo Models of Acute Respiratory Distress Syndrome.天然脯氨酰寡肽酶抑制剂在急性呼吸窘迫综合征体外和体内模型中的协同肺保护作用。
Int J Mol Sci. 2023 Sep 18;24(18):14235. doi: 10.3390/ijms241814235.
2
Secondary Infections in Patients with COVID-19 Pneumonia Treated with Tocilizumab Compared to Those Not Treated with Tocilizumab: A Retrospective Study at a Tertiary Hospital in Kenya.与未接受托珠单抗治疗的新型冠状病毒肺炎患者相比，接受托珠单抗治疗的新型冠状病毒肺炎患者的继发感染：肯尼亚一家三级医院的回顾性研究
Int J Gen Med. 2022 Mar 3;15:2415-2425. doi: 10.2147/IJGM.S356547. eCollection 2022.
本文引用的文献
1
Interleukin-6 blockade with tocilizumab in COVID-19: Does it live up to its hype?托珠单抗阻断白细胞介素-6治疗新型冠状病毒肺炎：它是否名副其实？
Pulmonology. 2021 Jan-Feb;27(1):86-87. doi: 10.1016/j.pulmoe.2020.10.004. Epub 2020 Oct 21.
2
COVACTA trial raises questions about tocilizumab's benefit in COVID-19.COVACTA试验引发了关于托珠单抗在新冠病毒肺炎中疗效的质疑。
Lancet Rheumatol. 2020 Oct;2(10):e592. doi: 10.1016/S2665-9913(20)30313-1. Epub 2020 Sep 9.
3
Rationale and evidence on the use of tocilizumab in COVID-19: a systematic review.托珠单抗在 COVID-19 中的应用的原理和证据：系统评价。
Pulmonology. 2021 Jan-Feb;27(1):52-66. doi: 10.1016/j.pulmoe.2020.07.003. Epub 2020 Jul 20.
4
Update I. A systematic review on the efficacy and safety of chloroquine/hydroxychloroquine for COVID-19.更新 I. 氯喹/羟氯喹治疗 COVID-19 的疗效和安全性的系统评价。
J Crit Care. 2020 Oct;59:176-190. doi: 10.1016/j.jcrc.2020.06.019. Epub 2020 Jul 11.
Zotero 插件